PATIENT REFERRAL CRITERIA

Patients with more than one of the following risk factors and who are New York Heart Association (NYHA) Class III or IV should be considered for referral for mechanical circulatory support (MCS) and/or cardiac transplantation evaluation.

Functional Assessment

- Inability to walk one block without shortness of breath
- Intolerant or refractory to ACE inhibitors, angiotensin receptor blockers, or beta-blockers
- One heart-failure–related hospital admission in the past 6 months
- CRT nonresponder
- High diuretic dose (eg, 120 mg/d furosemide)

Lab Assessment

- Serum sodium < 136 mmol/L
- BUN > 40 mg/dL or serum creatinine > 1.8 mg/dL
- Hematocrit < 35%
HeartMate II® provides dramatic and sustained improvements in quality of life for advanced stage heart failure patients.3-6

## Documented MCS Benefits

- Restoration of hemodynamics
- Reduced mortality
- Improvement in cardiac output
- Improvement in quality of life
- Improvement in end organ (renal/hepatic) function

### References


Thoratec Corporation, 6035 Stoneridge Drive, Pleasanton, CA 94588
1-925-847-8600 1-800-528-2577 www.thoratec.com

Thoratec, the Thoratec logo, and HeartMate II are registered trademarks of Thoratec Corporation. ©2012 Thoratec Corporation. All rights reserved. J074-0712

<table>
<thead>
<tr>
<th>NYHA Class I or II</th>
<th>Early Trial</th>
<th>Mid Trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>125</td>
<td>267</td>
</tr>
<tr>
<td>6 months</td>
<td>85</td>
<td>191</td>
</tr>
<tr>
<td>12 months</td>
<td>73</td>
<td>161</td>
</tr>
<tr>
<td>18 months</td>
<td>58</td>
<td>130</td>
</tr>
<tr>
<td>24 months</td>
<td>59</td>
<td>103</td>
</tr>
</tbody>
</table>

81% Improved to NYHA Class I or II